Literature DB >> 30584686

Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: A 18 F-FDOPA PET/CT study.

Vincent Amodru1, Pauline Romanet2, Ugo Scemama3, Marion Montava4, Nicolas Fakhry4, Frédéric Sebag5, Frédéric Castinetti1, Jean-Pierre Lavieille2, Anderson Loundou6, Arthur Varoquaux3, Anne Barlier2, Karel Pacak7, David Taïeb8,9.   

Abstract

BACKGROUND: 18 F-FDOPA PET/CT was proved to be a highly sensitive imaging method for detecting head and neck paraganglioma (HNPGL). The primary aim of the study was to evaluate the relationship between tumor characteristics and the SDHx-mutational status in a large series of patients with HNPGL evaluated by 18 F-FDOPA PET/CT.
METHODS: A total of 104 patients with HNPGL (65 sporadic/39 SDHx-mutated) were included.
RESULTS: In comparison to SDHB/SDC/SDHx-negative cases, patients with SDHD were younger at diagnosis and had a higher rate of multifocal, vagal, and carotid paraganglioma. In patients with SDHD, vagal paraganglia represented the primary site of tumor origin. Multicentric involvement of the vagus nerve alone or in association with other locations was found to be a typical feature of SDHD cases compared to other cases (odds ratio = 59.4).
CONCLUSION: The present study shows that tumor multifocality within the vagus nerve is a phenotypic marker of SDHD mutation. This information is essential in the choice of the therapeutic strategy.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  diagnostic imaging; genetics; paragangliomas; vagus nerve

Mesh:

Substances:

Year:  2018        PMID: 30584686      PMCID: PMC7350654          DOI: 10.1002/hed.25604

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  24 in total

1.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma.

Authors:  B E Baysal; R E Ferrell; J E Willett-Brozick; E C Lawrence; D Myssiorek; A Bosch; A van der Mey; P E Taschner; W S Rubinstein; E N Myers; C W Richard; C J Cornelisse; P Devilee; B Devlin
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

2.  The vagal body and its tumour.

Authors:  J H BIRRELL
Journal:  Aust N Z J Surg       Date:  1953-08

3.  Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients.

Authors:  Valentina Piccini; Elena Rapizzi; Alessandra Bacca; Giuseppe Di Trapani; Raffaele Pulli; Valentino Giachè; Benedetta Zampetti; Emanuela Lucci-Cordisco; Letizia Canu; Elisa Corsini; Antongiulio Faggiano; Luca Deiana; Davide Carrara; Valeria Tantardini; Stefano Mariotti; Maria Rosaria Ambrosio; Maria Chiara Zatelli; Gabriele Parenti; Annamaria Colao; Carlo Pratesi; Giampaolo Bernini; Tonino Ercolino; Massimo Mannelli
Journal:  Endocr Relat Cancer       Date:  2012-04-10       Impact factor: 5.678

Review 4.  Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas.

Authors:  Rodrigo A Toledo; Nelly Burnichon; Alberto Cascon; Diana E Benn; Jean-Pierre Bayley; Jenny Welander; Carli M Tops; Helen Firth; Trish Dwight; Tonino Ercolino; Massimo Mannelli; Giuseppe Opocher; Roderick Clifton-Bligh; Oliver Gimm; Eamonn R Maher; Mercedes Robledo; Anne-Paule Gimenez-Roqueplo; Patricia L M Dahia
Journal:  Nat Rev Endocrinol       Date:  2016-11-18       Impact factor: 43.330

Review 5.  New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.

Authors:  David Taïeb; Karel Pacak
Journal:  Trends Endocrinol Metab       Date:  2017-08-31       Impact factor: 12.015

6.  Mutations associated with succinate dehydrogenase D-related malignant paragangliomas.

Authors:  Henri J L M Timmers; Karel Pacak; Jérôme Bertherat; Jacques W M Lenders; Michèle Duet; Graeme Eisenhofer; Constantine A Stratakis; Patricia Niccoli-Sire; Ba Huy Patrice Tran; Nelly Burnichon; Anne-Paule Gimenez-Roqueplo
Journal:  Clin Endocrinol (Oxf)       Date:  2007-10-31       Impact factor: 3.478

7.  Vagal body tumor (nonchromaffin paraganglioma, chemodectoma, and carotid body-like tumor) with cervical node metastasis and familial association: ultrastructural study and review.

Authors:  L B Kahn
Journal:  Cancer       Date:  1976-12       Impact factor: 6.860

8.  Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.

Authors:  Aurélien Archier; Arthur Varoquaux; Philippe Garrigue; Marion Montava; Carole Guerin; Sophie Gabriel; Eva Beschmout; Isabelle Morange; Nicolas Fakhry; Frédéric Castinetti; Frédéric Sebag; Anne Barlier; Anderson Loundou; Benjamin Guillet; Karel Pacak; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-05       Impact factor: 9.236

9.  68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI.

Authors:  Ingo Janssen; Clara C Chen; David Taieb; Nicholas J Patronas; Corina M Millo; Karen T Adams; Joan Nambuba; Peter Herscovitch; Samira M Sadowski; Antonio T Fojo; Inga Buchmann; Electron Kebebew; Karel Pacak
Journal:  J Nucl Med       Date:  2015-11-12       Impact factor: 10.057

10.  Evaluation of Head and Neck Paragangliomas by Computed Tomography in Patients with Pheochromocytoma-Paraganglioma Syndromes.

Authors:  Ilona Michałowska; Anna Lewczuk; Jarosław Ćwikła; Aleksander Prejbisz; Urszula Swoboda-Rydz; Mariusz I Furmanek; Małgorzata Szperl; Andrzej Januszewicz; Mariola Pęczkowska
Journal:  Pol J Radiol       Date:  2016-10-31
View more
  1 in total

1.  Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: A 18 F-FDOPA PET/CT study in head and neck paragangliomas.

Authors:  Thibaut Reichert; Nicolas Fakhry; Jean-Pierre Lavieille; Vincent Amodru; Frédéric Sebag; Pauline Romanet; Anderson Loundou; Frédéric Castinetti; Karel Pacak; Marion Montava; David Taïeb
Journal:  Clin Endocrinol (Oxf)       Date:  2019-10-01       Impact factor: 3.523

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.